# US 2014/0155327 A1 · Process for the Synchronization of Ovulation for Timed Breeding Without Heat Detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0155327 A1
- Document ID: US20140155327A1
- Status: Published application
- Kind: A1
- Application number: 13/868,487
- Filed: 2013-04-23
- Published: 2014-06-05
- Earliest claimed: 2003-10-03
- Assignees: Thorn BioScience LLC
- Inventors: James W. Lauderdale
- Web page: https://patentgrep.com/patent/US20140155327A1

## CPC

- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61D 19/02: for artificial insemination
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0034: {Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/10: Dispersions; Emulsions
- A61K 38/24: Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61D: VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method for synchronizing ovulation in sows and gilts without heat detection by a single injection of hormones is disclosed. A hormone, gonadotropin releasing hormone (GnRH), luteinizing hormone (LH), follicle stimulating hormone (FSH), human chorionic gonadotropin (hCG), analogues, derivatives, agonists or combinations thereof is administered to an open sow post weaning at a specific time to stimulate ovulation of mature responsive follicles. The sow is then bred without heat detection at a specific subsequent timed interval after injection with hormone, with one or two artificial or natural breedings. In gilts, the hormone is injected at a timed interval from onset of estrus or at a specific timed interval following Prostaglandin F2a for those gilts which have been held in a state of pseudopregnancy.

## Claims

### Claim 1

A method of synchronizing time of insemination in a weaned sow, the method comprising the steps of:
a. administering a composition comprising a hormone selected from the group comprising a gonadotropin releasing hormone (GnRH) or an analog or derivative thereof in a controlled release, injectable excipient without sequential hormonal intervention, the controlled release, injectable excipient being selected from the group consisting of sucrose acetate isobutyrate (SAIB) and block copolymers based on ethylene oxide and propylene oxide and is administered to the sow after a timed interval post weaning;
b. breeding the sow at a defined time after administration of the hormone in a single artificial insemination step; and
c. carrying out the method without heat detection.

### Claim 2 (depends on 1)

The method of claim 1 wherein the excipient further includes a pharmaceutically acceptable organic solvent to form a low viscosity, injectable composition.

### Claim 3 (depends on 2)

The method of claim 2 wherein the acceptable organic solvent is selected from the group consisting of ethanol, NMP and Miglyol® 810.

### Claim 4 (depends on 1)

The method of claim 1 wherein the hormone is GnRH.

### Claim 5 (depends on 1)

The method of claim 1 wherein the hormone is deslorelin.

### Claim 6 (depends on 2)

The method of claim 2 wherein the composition comprises deslorelin in an admixture of sucrose acetate isobutyrate (SAIB) and ethanol.

### Claim 7 (depends on 1)

The method of claim 1 wherein the hormone is administered in a dosage amount effective to stimulate ovarian follicle ovulation.

### Claim 8 (depends on 1)

The method of claim 1 wherein the hormone is an analog of GnRH and the dosage rate is the amount equivalent to the native form hormone.

### Claim 9 (depends on 1)

The method of claim 1 wherein the gonadotropin releasing hormone is administered in a dose ranging from between 10 mcg to about 100 mcg.

### Claim 10 (depends on 1)

The method of claim 1 wherein the sow is bred about 28 hours after administration of the composition.

### Claim 11 (depends on 1)

The method of claim 1 wherein the hormone is a native form of GnRH.